35,718 Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Bought by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 35,718 shares of the biotechnology company’s stock, valued at approximately $262,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after acquiring an additional 535,301 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Aurinia Pharmaceuticals in the third quarter worth about $3,330,000. Stonepine Capital Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth about $1,713,000. AQR Capital Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at about $1,155,000. Finally, Algert Global LLC raised its holdings in Aurinia Pharmaceuticals by 106.8% in the 2nd quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock worth $1,107,000 after purchasing an additional 100,104 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $8.88 on Friday. The firm has a 50-day simple moving average of $7.74 and a 200-day simple moving average of $6.56. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -59.20 and a beta of 1.41. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $9.74.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the transaction, the director now owns 13,356 shares in the company, valued at $112,591.08. The trade was a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AUPH shares. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. Finally, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.